Shalender Bhasin
Works at
Professor
Sources: reporter.nih.gov
Member of
Joint principal investigator
Sources: assets-us-01.kc-usercontent.com
Grants and prizes
R01, Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People with Down Syndrome, R01AG088141, 2025–2028, 9 Sept 2026
U01, Development, Validation, and Harmonization of Methods for Collection and Measurement of NAD+ and Related Metabolites: Application to a Randomized Trial of Patients Undergoing Coronary Artery Bypass, U01AG089040, 2024–2029, 25 Aug 2026
P30, Boston OAIC: A Translational Approach to Function Promoting Therapies, P30AG031679, 2008–2031, 24 Aug 2026
UG3, Repurposing a Reverse Transcriptase Inhibitor To Target Retrotransposons and Prevent Alzheimer's Disease in People with Down Syndrome: A Two-Phase UG3/UH3 Clinical Drug Development Program, UG3AG101657, 2026–2028, 6 Aug 2026
U01, NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial, U01AG076789, 2022–2026, 26 May 2026
National Institute of Diabetes and Digestive and Kidney Diseases
R01, A Pilot Study to Evaluate the Anabolic Effect of Testosterone on Muscles of the Pelvic Floor in Older Women with Stress Urinary Incontinence, R01DK136904, 2023–2027, 3 Jul 2025
R01, A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease, R01AG071074, 2021–2026, 5 Jun 2024
Sources: reporter.nih.gov